Humacyte reports Q2 2026 results and positive Phase 3 dialysis trial data

Humacyte has released its second quarter 2026 financial results and a business update, highlighted by interim data from its V012 Phase 3 trial. The trial, involving acellular tissue engineered vessels (ATEV) in female dialysis patients, showed that ATEV outperformed AV fistula, resulting in an average of 91 more catheter-free days and lower infection rates.

Based on these results, the company plans to file a supplemental Biologics License Application (sBLA) for dialysis access with the FDA in the second half of 2026. Additionally, the FDA has accepted an Investigational New Drug (IND) application for a Phase 2a study using its coronary tissue engineered vessel (CTEV) for CABG, which is expected to begin in Q3 2026.

Financially, Symvess sales rose to $0.4 million in Q2 2026, up from $0.1 million in the previous year. Despite a quarterly net loss of $36.8 million, Humacyte ended June 30, 2026, with $80.3 million in cash and cash equivalents following a $57.5 million public equity offering. The company also expects to achieve approximately $14.3 million in cost savings through restructuring during 2026.